Targets › MC4R
3 programs from 2 companies in 6 trials: 2 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4; Metabolic and endocrine; next expected readout Mar 2027.
G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha- and beta-MSH) and corticotropin/ACTH, which are peptide products of the POMC precursor. Functions as a central component of the leptin-melanocortin pathway, which is essential for maintaining energy homeostasis. (UniProt, P32245)
Open in Phaseline: the race on MC4R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | Setmelanotide Melanocortin receptor 4 agonist | MC4R | Phase 3 | Hypothalamic Obesity; Prader-Willi Syndrome; Bardet Biedl Syndrome (BBS) | Mar 2027 |
| Palatin Technologies | bremelanotide Melanocortin receptor 4 agonist | MC4R | Phase 2 | Obesity | – |
| Rhythm Pharmaceuticals | RM-718 MC4R (melanocortin 4 receptor) agonist | MC4R | Phase 1 | Hypothalamic Obesity | May 2027 |
Hypothalamic Obesity (3) Obesity (1) Prader-Willi Syndrome (1) Bardet Biedl Syndrome (BBS) (1)
protein or peptide (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.